Day Zero Diagnostics
Day Zero Diagnostics develops genome sequencing-based diagnostic solutions for infectious diseases, combining machine learning and whole-genome sequencing to rapidly identify infecting bacterial species and drug resistance profiles. The company's key assays include Blood2Bac, a culture-free bacterial enrichment technology, and BacDetect, which uses whole-genome sequencing to detect both species and antimicrobial…
Funding snapshot
About
Day Zero Diagnostics develops genome sequencing-based diagnostic solutions for infectious diseases, combining machine learning and whole-genome sequencing to rapidly identify infecting bacterial species and drug resistance profiles. The company's key assays include Blood2Bac, a culture-free bacterial enrichment technology, and BacDetect, which uses whole-genome sequencing to detect both species and antimicrobial resistance directly from clinical samples. This approach aims to reduce the time to actionable diagnostic results from days to hours, addressing the critical need for rapid diagnostics in sepsis and other severe bacterial infections. Founded in 2016 and headquartered in Boston, Massachusetts, Day Zero Diagnostics has raised approximately $49 million in Series B funding from investors including CARB-X, NIH, Becton Dickinson, Sands Capital Ventures, Triventures, and Panacea Venture.
Business model
Infectious Diseases > In Vitro Diagnostic Tests > Bacterial > Multi Drug Resistant,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Infectious Diseases,
MassChallenge Batches > HealthTech > 2018
Team background
College Wise > Massachusetts Institute of Technology, Harvard University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Day Zero Diagnostics?
Analyze your pitch deck before your next raise.
Analyze My Deck →